Bluish-white soft malleable metal or gray granules.
In semiconductor research. Alloyed with mercury for switches and closures which operate at subzero temperatures.
Registry Numbers and Inventories.
EC Index Number
Very toxic; Danger of cumulative effects; Dangerous for the Environment
U214; U215; U216; U217; P113; P115
Swiss Giftliste 1
Melting point, °C
Boiling point, °C
11.85 g/cm3 (20 C)
Solubility in water
0.000128/K (302 C)
Heat of fusion
Heat of vaporization
Hazards and Protection.
Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.
All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.
Employees should be provided with and required to use impervious clothing, gloves, face shields (eight-inch minimum), and other appropriate protective clothing necessary to prevent skin contact with soluble thallium compounds where skin contact may occur. Employees should be provided with and required to use dust and splash proof safety goggles where soluble thallium compounds may contact the eyes. Thallium and thallium compounds.
Use NIOSH/MSHA approved respirator appropriate for exposure of concern.
Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.
Strong oxidizing agents.
When heated to decomposition, emits toxic fumes of thallium.
Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.
Moderate as dust exposed to heat or flame.
TLV (as Tl (soluble compounds)): ppm; 0.1 mg/m3 (as TWA) (skin) (ACGIH 994-1995). OSHA PEL: TWA 0.1 mg/m3 skin NIOSH REL: TWA 0.1 mg/m3 skin NIOSH IDLH: 15 mg/m3 (as Tl)
Early effects may include paresthesias, myalgias, peripheral burning sensation, headache, cranial nerve palsies, seizures, delirium, coma, peripheral neuropathy, severe pain, and muscle weakness/atrophy. Protracted cases may develop ataxia, choreiform movements, dementia, depression and psychosis. Neurological damage resolves slowly and may be permanent.
Gi symptoms may include anorexia, salivation, diarrhea, constipation, stomatitis, severe paroxysmal abdominal pain, vomiting, and hemorrhage.
Respiratory failure or ards may develop in severe cases.
Severe acne, hair pigmentation, mees lines, and alopecia may occur.
Optic neuritis, decreased visual acuity and impaired color vision may occur.
Administer charcoal as a slurry (240 ml water/30 g charcoal). Usual dose: 25 to 100 g in adults/adolescents. Consider after ingestion of a potentially life-threatening amount of poison if it can be performed soon after ingestion (generally within 1 hour). Monitor cardiac, renal and hepatic function. Prussian blue: although preferred in europe, prussian blue is not commercially available in the us and is not fda-approved. Contraindications: diethylthiocarbamate has been reported to result in dangerous redistribution of thallium to the cns and is contraindicated. Potassium chloride - has been reported to enhance elimination with equivocal results; can acutely worsen neurological symptoms.
If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.
Remove contaminated clothing and wash exposed area thoroughly with soap and water. A physician should examine the area if irritation or pain persists.
Irrigate exposed eyes with copious amounts of tepid water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist, the patient should be seen in a health care facility.
USCG CHRIS Code